I Rhythm Technologies, Inc. IRTC
We take great care to ensure that the data presented and summarized in this overview for iRhythm Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRTC
View all-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct20MShares$3.42 Billion1.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$553 Million0.01% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.57MShares$439 Million0.67% of portfolio
-
Black Rock Inc. New York, NY2.5MShares$427 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA2.24MShares$382 Million1.11% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.18MShares$202 Million0.04% of portfolio
-
State Street Corp Boston, MA848KShares$145 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA790KShares$135 Million0.01% of portfolio
-
Blair William & CO Chicago, IL741KShares$127 Million0.35% of portfolio
-
Eventide Asset Management, LLC Boston, MA692KShares$118 Million2.19% of portfolio
Latest Institutional Activity in IRTC
Top Purchases
Top Sells
About IRTC
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Transactions at IRTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2025
|
Patrick Michael Murphy CBO and CLO |
SELL
Open market or private sale
|
Direct |
2,478
-4.44%
|
$455,952
$184.83 P/Share
|
|
Dec 02
2025
|
Chad Patterson CHIEF COMM & PRODUCT OFFICER |
SELL
Open market or private sale
|
Direct |
280
-0.64%
|
$51,520
$184.83 P/Share
|
|
Nov 28
2025
|
Minang Turakhia CHIEF MED/SCI OFCR EVP ADVTECH |
BUY
Grant, award, or other acquisition
|
Direct |
250
+0.6%
|
$18,500
$74.72 P/Share
|
|
Nov 28
2025
|
Marc W. Rosenbaum Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2
+0.02%
|
$238
$119.55 P/Share
|
|
Nov 28
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73
+0.21%
|
$8,687
$119.55 P/Share
|
|
Nov 10
2025
|
Abhijit Y Talwalkar Director |
SELL
Open market or private sale
|
Direct |
5,312
-3.77%
|
$924,288
$174.71 P/Share
|
|
Nov 10
2025
|
Abhijit Y Talwalkar Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,312
+17.18%
|
$53,120
$10.71 P/Share
|
|
Nov 03
2025
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
14,059
-7.85%
|
$2,558,738
$182.94 P/Share
|
|
Oct 31
2025
|
Daniel G. Wilson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,000
-23.21%
|
$1,656,000
$207.44 P/Share
|
|
Sep 03
2025
|
Daniel G. Wilson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-12.67%
|
$875,000
$175.0 P/Share
|
|
Sep 02
2025
|
Daniel G. Wilson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
737
-1.83%
|
$123,079
$167.28 P/Share
|
|
Aug 22
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
653
-1.88%
|
$109,051
$167.12 P/Share
|
|
Aug 11
2025
|
Abhijit Y Talwalkar Director |
SELL
Open market or private sale
|
Direct |
5,312
-10.96%
|
$839,296
$158.13 P/Share
|
|
Aug 11
2025
|
Abhijit Y Talwalkar Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,312
+17.18%
|
$53,120
$10.71 P/Share
|
|
Aug 11
2025
|
Marc W. Rosenbaum Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
226
-2.04%
|
$35,708
$158.93 P/Share
|
|
Aug 06
2025
|
Chad Patterson CHIEF COMM & PRODUCT OFFICER |
SELL
Open market or private sale
|
Direct |
2,555
-5.53%
|
$403,690
$158.97 P/Share
|
|
Aug 05
2025
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.17%
|
$4,830,000
$161.97 P/Share
|
|
Aug 04
2025
|
Chad Patterson CHIEF COMM & PRODUCT OFFICER |
SELL
Open market or private sale
|
Direct |
2,707
-5.53%
|
$443,948
$164.36 P/Share
|
|
Aug 04
2025
|
Mervin Smith EVP Strategic Business Ops |
SELL
Open market or private sale
|
Direct |
616
-3.74%
|
$101,024
$164.36 P/Share
|
|
Jul 07
2025
|
Kevin C Oboyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,035
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 264K shares |
|---|---|
| Exercise of conversion of derivative security | 10.6K shares |
| Open market or private sale | 188K shares |
|---|